Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04172597 · ClinicalTrials.gov registry record · Phase 2
A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies
A Phase 2 study, sponsored by Spectrum Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT04172597 is a Phase 2 study that was terminated before completion, run by Spectrum Pharmaceuticals. The registered enrollment target is 1 participants.
The verdict
NCT04172597, a Phase 2 study, was terminated before completion, sponsored by Spectrum Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a Phase 2, open-label, multicenter study whose principal objectives are to evaluate the efficacy and safety/tolerability of poziotinib in five cohorts of 30 previously-treated patients each.
Interventions
- DRUG Loperamide
- DRUG Poziotinib Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-12-23 |
| Est. Completion | 2022-03-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04172597
The ClinicalTrials.gov registry entry for NCT04172597 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spectrum Pharmaceuticals, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Loperamide is the first listed.
NCT04172597 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04172597 about?
NCT04172597 is a clinical study titled "A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies". This is a Phase 2, open-label, multicenter study whose principal objectives are to evaluate the efficacy and safety/tolerability of poziotinib in five cohorts of 30 previously-treated patients each.
What is the current status of trial NCT04172597?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2019-12-23. Estimated completion is 2022-03-29.
What interventions are being tested in trial NCT04172597?
The interventions under investigation include: Loperamide (DRUG), Poziotinib Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT04172597?
This trial is sponsored by Spectrum Pharmaceuticals, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.